Oncology-focused CRO OncoBay has signed up to use physIQ’s latest patient monitoring system to track participants during their clinical trial journey.
The Tampa, Florida-based research center, a subsidiary of the Moffit Cancer Center, will use physIQ’s Intrepid Partner Program to monitor and evaluate these patients and the effectiveness of treatments in near real-time through high-fidelity, medical-grade biosensor data streams.
PhysIQ debuted the program earlier this month with the goal of attracting CROs, academic research organizations and other tech companies with its portfolio of AI-based digital biomarkers, experience with government regulators and other technologies in clinical operations.
The program’s “predict-to-prevent” pharmacovigilance model was a big attraction for OncoBay, as it can provide early detection of inflammation and other adverse events that can otherwise increase the cost burden of trialing immuno-oncology and other cell and gene therapies, the CRO said in a Nov. 15 release.
“By using physIQ, we’re getting to the direct source of information through raw data collected from a patient’s physiology giving us the ability to make smarter decisions about patient care without relying on an interpretation of data that may lead to incorrect assumptions,” OncoBay CEO Krystyna Kowalczyk said.
The Intrepid Partner Program is also designed to help diversify clinical trials through the recruitment of patients from underrepresented populations, which has been a growing focus in the clinical trial arena.